BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30219990)

  • 1. Comparison of
    Palard-Novello X; Beuzit L; Gambarota G; Le Jeune F; Garin E; Salaün PY; Devillers A; Querellou S; Bourguet P; Saint-Jalmes H
    Ann Nucl Med; 2019 Jan; 33(1):47-54. PubMed ID: 30219990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of choline influx from dynamic
    Palard-Novello X; Blin AL; Bourhis D; Garin E; Salaün PY; Devillers A; Querellou S; Bourguet P; Le Jeune F; Saint-Jalmes H
    Ann Nucl Med; 2018 May; 32(4):281-287. PubMed ID: 29492810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
    How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
    Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kwak C; Kang KW; Chung JK; Kim EE; Lee DS
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1247-56. PubMed ID: 25759164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    Reynolds HM; Williams S; Jackson P; Mitchell C; Hofman MS; Hicks RJ; Murphy DG; Haworth A
    BJU Int; 2019 Jun; 123(6):1020-1030. PubMed ID: 30536698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of
    Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
    Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
    Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
    Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
    Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.
    Wetter A; Lipponer C; Nensa F; Heusch P; Rübben H; Altenbernd JC; Schlosser T; Bockisch A; Pöppel T; Lauenstein T; Nagarajah J
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):79-88. PubMed ID: 24085502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
    Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
    J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
    Achard V; Lamanna G; Denis A; De Perrot T; Mainta IC; Ratib O; Iselin C; Miralbell R; Garibotto V; Zilli T
    Med Oncol; 2019 Jun; 36(8):67. PubMed ID: 31190232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE; Kairemo K
    Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-weighted MRI,
    Kitajima K; Yamamoto S; Kawanaka Y; Nakanishi Y; Yamada Y; Go S; Kanematsu A; Kaida H; Yamakado K
    Hell J Nucl Med; 2020; 23(1):34-39. PubMed ID: 32222730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.